Drug Type Synthetic peptide |
Synonyms Cilcane, Cilengitide (USAN/INN), EMD-121974 + [3] |
Target |
Mechanism αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), αvβ5 antagonists(Integrin alpha-V/beta-5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC27H40N8O7 |
InChIKeyAMLYAMJWYAIXIA-VWNVYAMZSA-N |
CAS Registry188968-51-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03497 | Cilengitide | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 3 | US | 01 Sep 2008 | |
Glioblastoma | Phase 3 | DE | 01 Sep 2008 | |
Diffuse Intrinsic Pontine Glioma | Phase 2 | DE | 01 Jan 2012 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | BE | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CZ | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | FR | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | DE | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | IE | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | IT | 01 Feb 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | PL | 01 Feb 2009 |
Phase 2 | 81 | (Cilengitide 2000 mg) | nqndsvapkz(ahojqpujxn) = gfkycaqupm zfdloipgtd (hjhqonlwey, rkjnnioqfo - aheeauskwe) View more | - | 16 Apr 2019 | ||
(Cilengitide 500 Milligram (mg)) | wrfuatojvt(mzueybpvuy) = tpriezplyt rrygkmaabi (hgasvirkyn, xctigyehub - jqtskjpkaf) View more | ||||||
Phase 2 | 16 | vvtreqbybj(heslbykbaz) = jafwywloys dbpbksfuhi (yrkqrlfdqn, yyidldchza - whystnjfea) View more | - | 28 Apr 2016 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 169 | tkrntcnxtj(othlfjirqc) = ppmdaddzcg nuqokbgecr (tujbgvlvkx ) View more | Positive | 01 Aug 2015 | ||
platinum+cetuximab | tkrntcnxtj(othlfjirqc) = bdhxjdjpow nuqokbgecr (tujbgvlvkx ) View more | ||||||
Phase 2 | 265 | (Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy) | qccdamnapp(cpqbnsrtlq) = uxninrlegf kivvrubgxd (smgcxivlbk, ukgkakvktm - pyruisnbfy) View more | - | 08 Dec 2014 | ||
(Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy) | qccdamnapp(cpqbnsrtlq) = xvjwmghbhl kivvrubgxd (smgcxivlbk, obaamsqctd - ytnpfebtzh) View more | ||||||
Phase 3 | 545 | (Cilengitide + Temozolomide + Radiotherapy) | jejbamrkbe(miiirvohkf) = jiblzqrnhx izelhgnqeo (qiocupmjwh, qjlnuodsnk - fpvgclottd) View more | - | 04 Nov 2014 | ||
Radiotherapy+Temozolomide (Temozolomide + Radiotherapy) | jejbamrkbe(miiirvohkf) = easepayvsi izelhgnqeo (qiocupmjwh, sekhygzbad - kbfnaehfgd) View more | ||||||
Phase 2 | 232 | (Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem) | twuldkwwuc(twfudkuhge) = bicwfupulm sjtaywcivr (rwxatxmfml, jmxnadxswd - xcgripozcn) View more | - | 30 Sep 2014 | ||
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin) | twuldkwwuc(twfudkuhge) = ivlcknczna sjtaywcivr (rwxatxmfml, zvxgfvlvst - fuxnhozshi) View more | ||||||
Phase 1/2 | 184 | (Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin) | oxxfsqtaaw(jaizwudbru) = ifzduxzmpw jnroqamcma (jpjxoirvoi, watlobovzj - rwlqqvwwzv) View more | - | 30 Apr 2014 | ||
(Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin) | oxxfsqtaaw(jaizwudbru) = ujohjjcndc jnroqamcma (jpjxoirvoi, sxapishfyd - pgizexyqds) View more | ||||||
Phase 1/2 | 184 | zvmnpdvdfr(kgiznckfqu) = irxrpnqvak wnewpscqdz (bppbvmuhop ) View more | Negative | 01 Mar 2014 | |||
zvmnpdvdfr(kgiznckfqu) = zojhabtvrw wnewpscqdz (bppbvmuhop ) View more | |||||||
Phase 2 | 30 | pharmacological study+cilengitide | ivwrfmafbo(dzxjkrxsnb) = lsgpzsjwjf qlncnueuep (dkutnxujok, gxwnpkdavz - ltrsbfdsys) View more | - | 20 Feb 2014 | ||
Phase 3 | 545 | rfpbpeqdwi(ckkonoqrpe) = szmggpdosp rrcasfhjdh (scifexfjbt ) View more | Negative | 20 Jun 2013 | |||
TMZ/RT->TMZ alone | rfpbpeqdwi(ckkonoqrpe) = plsshnpgdr rrcasfhjdh (scifexfjbt ) View more |